PCAF fine‐tunes hepatic metabolic syndrome, inflammatory disease, and cancer
| Autor: | Ruilong Zheng, Weilei Yao, Yafei Shao, Feiruo Huang, Tongxin Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Reviews Disease Review Biology 03 medical and health sciences 0302 clinical medicine Neoplasms Gene expression PCAF medicine cancer Humans p300-CBP Transcription Factors Pathological hepatic metabolic syndrome chemistry.chemical_classification Inflammation Metabolic Syndrome Cancer Cell Biology Histone acetyltransferase medicine.disease inflammatory disease 030104 developmental biology Enzyme chemistry Liver 030220 oncology & carcinogenesis biology.protein Cancer research fine‐tuning Molecular Medicine Metabolic syndrome Inflammation Mediators |
| Zdroj: | Journal of Cellular and Molecular Medicine |
| ISSN: | 1582-4934 1582-1838 |
| Popis: | The P300/CBP‐associating factor (PCAF), a histone acetyltransferase, is involved in metabolic and pathogenic diseases, particularly of the liver. The effects of PCAF on fine‐tuning liver diseases are extremely complex and vary according to different pathological conditions. This enzyme has dichotomous functions, depending on differently modified sites, which regulate the activities of various enzymes, metabolic functions, and gene expression. Here, we summarize the most recent findings on the functions and targets of PCAF in various metabolic and immunological processes in the liver and review these new discoveries and models of PCAF biology in three areas: hepatic metabolic syndrome, inflammatory disease, and cancer. Finally, we discuss the potential implications of these findings for therapeutic interventions in liver diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text